Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qidong Huoluo Granule is a traditional Chinese medicine (TCM) compound formulated as a granule, containing ingredients such as Astragalus, Ophiopogon, and other herbs. It is designed by a research team affiliated with traditional medicine in China and administered orally, typically twice daily[1][4]. The compound is used adjunctively in amyotrophic lateral sclerosis (ALS) and has been studied in combination with electroacupuncture. Its purported benefits include stabilization of symptoms related to bulbar paralysis, improvements in swallowing, speech, articulation, and breathing in ALS patients[1][2][4]. Mechanistically, although the precise pharmacological action is not well characterized by modern standards, it is believed to work via antioxidative and anti-inflammatory effects, possibly mitigating neurodegeneration and oxidative stress, and supporting neuronal health through effects observed in metabolomic and gut microbiota studies[4]. The formula does not represent a single chemical entity but rather a multi-herb mixture typical of TCM compounds.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qidong Huoluo Granule.